Rocket Lab’s Classified Hypersonic Test and $200M Quarter Highlight a Pivotal Week for Space Stocks

A secret mission leaves the launchpad on Wednesday, a record backlog swells to $2.2 billion, and the industry’s biggest initial public offering in history is just three days away. For Rocket Lab, the convergence of these events is reshaping the narrative around a stock that has already climbed more than 50% this year.

The company, which operates a modified version of its Electron rocket known as HASTE (Hypersonic Accelerator Suborbital Test Electron), is scheduled to launch a classified payload from NASA’s Wallops Flight Facility in Virginia on Wednesday. Dubbed “Curveball,” the mission is part of a growing portfolio of hypersonic test contracts for the U.S. Department of Defense. The launch window opens at 9:00 a.m. PDT, and Rocket Lab has disclosed no further details about the customer or payload.

CEO Peter Beck recently framed the company’s position in stark terms. In his view, only two players globally—SpaceX and Rocket Lab—are capable of high-frequency orbital launches with consistent reliability. He pointed to the failure of more than 140 small-launch startups to achieve commercial traction, underscoring the widening moat around the incumbents.

That thesis is backed by numbers. Rocket Lab reported first-quarter 2026 revenue of $200 million, a 63.5% year-over-year surge that beat the consensus estimate of roughly $190 million. Non-GAAP gross margin improved to 43%. For the current quarter, management guided for revenue between $225 million and $240 million, well ahead of the $205 million analysts had modeled.

Wall Street responded quickly. Stifel analyst Erik Rasmussen raised his price target from $110 to $132, citing strong execution and increasing exposure to national security missions. Clear Street followed with an increase from $98 to $129. Institutional investors also moved: Capital World Investors boosted its stake by 12% to 16.2 million shares, a position worth roughly $1.13 billion, while Winton Group opened a new holding.

Should investors sell immediately? Or is it worth buying Rocket Lab?

Rocket Lab’s competitive standing received an indirect boost when Blue Origin’s New Glenn rocket reportedly suffered a test failure. The setback reinforces confidence in Rocket Lab’s established Electron program and the in-development Neutron medium-lift vehicle, which will directly target the same market segment as SpaceX’s Falcon 9.

The most anticipated near-term catalyst arrives on Friday, June 12, when SpaceX goes public at an expected valuation of $1.77 trillion and an offering price of $135 per share. Market observers anticipate a halo effect that could lift the entire space sector, with Rocket Lab viewed as the most liquid pure-play alternative for investors seeking exposure to integrated launch services.

Despite the bullish backdrop, Rocket Lab’s stock has not been immune to profit-taking. The shares closed Tuesday at €101.60, up nearly 4% on the day, but still roughly 27% below the all-time high of €133.80 reached in late May. The pullback followed a 8% decline over seven trading days amid a broader rotation out of space-related names. The 30-day annualized volatility stands at 131%, and the relative strength index sits at 50.6—technically neutral, leaving room for moves in either direction.

A more fundamental driver looms beyond the immediate IPO excitement. The development of Neutron, a medium-lift rocket designed to challenge SpaceX’s Falcon 9, represents the company’s next major growth inflection point. With a record order book that includes an $816 million contract from the Space Development Agency and a $190 million deal for the HASTE hypersonic program, Rocket Lab’s backlog provides a multiyear revenue runway that few competitors can match.